Clinical trial

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial

NCT06256237

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention JS004 Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Toripalimab Normalized identity: toripalimabView linked drug · Find medicine records · Find other trials using this name

PROCEDURE · Unmapped registry intervention surgery Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Etoposide Normalized identity: etoposideView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Platinum Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-04-01

PhasePHASE2

Conditions

Limited Stage Small Cell Lung Cancerunresolved

Interventions

JS004DRUG

ToripalimabDRUG · verified · RxNorm: toripalimab

surgeryPROCEDURE

EtoposideDRUG · verified · RxNorm: etoposide

PlatinumDRUG

Sponsors & collaborators

Shanghai Pulmonary Hospital, Shanghai, Chinalead sponsor

Mapped research locations

ShanghaiChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06256237 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.